Maddalena Sansovini
IRCCS IRST · IRST IRCCS · IRST IRCCS, Meldola
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Maddalena Sansovini as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:24 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06045260 · "Receptor Radionuclide Therapy With 177Lu-DOTATOCIstituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · recruiting · Neuroendocrine Tumors, Paraganglioma, Pheochromocytoma · study chair
- Ph2NCT05867615 · Radiometabolic Therapy With 177Lu PSMA in PSMA PET/CT Positive Advanced/Metastatic Tumours:Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · active not recruiting · Cancer · principal investigator
- Ph2NCT03454763 · Optimizing the Interval Between Cycles of PRRT with 177lu-dotatate in Sstr2 Positive TumorsIstituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · unknown · Neuroendocrine Tumors · study chair
- Ph2NCT02489604 · Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in Advanced Gastro-entero Pancreatic Neuroendocrine TumorsIstituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · terminated · Neuroendocrine Tumors · principal investigator
- Ph2NCT02488512 · Peptide Receptor Radionuclide Therapy With 90Y-Dotatoc in Relapsed/Refractory Diffuse Large B Cell and Mantle Cell LymphomasIstituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS · terminated · DLBCL, MCL, Recurrent Disease · principal investigator
- Ph1/Ph2NCT01240720 · A Dose Finding and Efficacy Study of the Tumour Targeting Human 131I-F16SIP Monoclonal Antibody in Patients With CancerPhilogen S.p.A. · completed · Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 09:24 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 09:24 UTC. The ranking covers the 200 most relevant of 14 PubMed records, and a shared surname and initials can bring in a namesake. All 14 on PubMed
- Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study.Eur J Nucl Med Mol Imaging · 2011341 citationsRCR 12.0
- Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors.Eur J Nucl Med Mol Imaging · 2008338 citationsRCR 9.8
- Peptide receptor radionuclide therapy with (90)Y-DOTATOC in recurrent meningioma.Eur J Nucl Med Mol Imaging · 2009107 citationsRCR 3.1
- 177 Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study.Eur J Nucl Med Mol Imaging · 201495 citationsRCR 3.9
- Peptide receptor radionuclide therapy with (177)Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and (18)F-FDG PET.Eur J Nucl Med Mol Imaging · 201681 citationsRCR 3.5
- Treatment with the radiolabelled somatostatin analog Lu-DOTATATE for advanced pancreatic neuroendocrine tumors.Neuroendocrinology · 201380 citationsRCR 3.1
- (18)F-FDG PET/CT in the evaluation of recurrent ovarian cancer: a prospective study on forty-one patients.Eur J Surg Oncol · 200569 citationsRCR 2.3
- Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors.Eur J Nucl Med Mol Imaging · 202156 citationsRCR 4.1
- 53 citationsRCR 4.2
- Dosimetry and safety of 177Lu PSMA-617 along with polyglutamate parotid gland protector: preliminary results in metastatic castration-resistant prostate cancer patients.Eur J Nucl Med Mol Imaging · 202050 citationsRCR 2.7